LS Investment Advisors’s AbbVie ABBV Stock Holding History

LS Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.23M	Sell	12,835 -759	-6%	-$163K	0.44%	49
2026 Q1	$2.96M	Buy	13,594 +2,611	+24%	+$579K	0.44%	49
2025 Q4	$2.51M	Buy	10,983 +1,084	+11%	+$247K	0.35%	47
2025 Q3	$2.29M	Buy	9,899 +493	+5%	+$100K	0.32%	49
2025 Q2	$1.75M	Buy	9,406 +15	+0.2%	+$2.79K	0.26%	56
2025 Q1	$1.97M	Sell	9,391 -2,443	-21%	-$475K	0.3%	54
2024 Q4	$2.1M	Sell	11,834 -444	-4%	-$81.6K	0.31%	54
2024 Q3	$2.42M	Buy	12,278 +4	+0%	+$747	0.36%	53
2024 Q2	$2.11M	Buy	12,274 +218	+2%	+$36.1K	0.33%	59
2024 Q1	$2.2M	Buy	12,056 +404	+3%	+$69.6K	0.35%	58
2023 Q4	$1.81M	Buy	11,652 +45	+0.4%	+$6.56K	0.31%	58
2023 Q3	$1.73M	Buy	11,607 +4	+0%	+$587	0.33%	56
2023 Q2	$1.56M	Sell	11,603 -1	-0%	-$147	0.27%	61
2023 Q1	$1.85M	Sell	11,604 -884	-7%	-$135K	0.34%	55
2022 Q4	$2.02M	Sell	12,488 -4,191	-25%	-$643K	0.39%	51
2022 Q3	$2.24M	Buy	16,679 +1,939	+13%	+$278K	0.45%	51
2022 Q2	$2.26M	Buy	14,740 +815	+6%	+$125K	0.42%	51
2022 Q1	$2.26M	Buy	13,925 +499	+4%	+$72.5K	0.36%	51
2021 Q4	$1.82M	Sell	13,426 -5,829	-30%	-$689K	0.27%	58
2021 Q3	$2.08M	Buy	19,255 +2,635	+16%	+$301K	0.27%	57
2021 Q2	$1.87M	Sell	16,620 -61,887	-79%	-$6.97M	0.24%	60
2021 Q1	$8.5M	Sell	78,507 -14,245	-15%	-$1.52M	0.47%	49
2020 Q4	$9.94M	Buy	92,752 +2,902	+3%	+$279K	0.52%	47
2020 Q3	$7.87M	Buy	89,850 +1,656	+2%	+$156K	0.45%	54
2020 Q2	$8.66M	Buy	88,194 +14,111	+19%	+$1.24M	0.54%	42
2020 Q1	$5.64M	Sell	74,083 -14,715	-17%	-$1.25M	0.41%	58
2019 Q4	$7.86M	Sell	88,798 -954	-1%	-$79.2K	0.42%	50
2019 Q3	$6.8M	Buy	89,752 +13,497	+18%	+$925K	0.4%	55
2019 Q2	$5.54M	Buy	76,255 +9,124	+14%	+$717K	0.34%	69
2019 Q1	$5.41M	Buy	67,131 +551	+0.8%	+$45.1K	0.34%	70
2018 Q4	$6.14M	Buy	66,580 +10,233	+18%	+$900K	0.43%	53
2018 Q3	$5.33M	Buy	56,347 +4,373	+8%	+$415K	0.31%	73
2018 Q2	$4.82M	Buy	51,974 +1,711	+3%	+$167K	0.29%	74
2018 Q1	$4.76M	Sell	50,263 -5,791	-10%	-$636K	0.28%	76
2017 Q4	$5.42M	Sell	56,054 -2,899	-5%	-$273K	0.32%	66
2017 Q3	$5.24M	Sell	58,953 -26,005	-31%	-$1.98M	0.31%	67
2017 Q2	$6.16M	Sell	84,958 -2,711	-3%	-$182K	0.38%	56
2017 Q1	$5.71M	Buy	87,669 +11,772	+16%	+$740K	0.37%	57
2016 Q4	$4.75M	Sell	75,897 -7,333	-9%	-$448K	0.34%	58
2016 Q3	$5.25M	Sell	83,230 -11,889	-12%	-$770K	0.39%	53
2016 Q2	$5.89M	Buy	95,119 +8,188	+9%	+$499K	0.41%	53
2016 Q1	$4.96M	Sell	86,931 -2,687	-3%	-$150K	0.37%	59
2015 Q4	$5.31M	Buy	89,618 +18,232	+26%	+$1.05M	0.41%	54
2015 Q3	$3.88M	Sell	71,386 -4,740	-6%	-$309K	0.31%	66
2015 Q2	$5.12M	Sell	76,126 -6,751	-8%	-$441K	0.38%	56
2015 Q1	$4.85M	Buy	82,877 +1,417	+2%	+$85.6K	0.37%	60
2014 Q4	$5.33M	Sell	81,460 -7,618	-9%	-$480K	0.43%	50
2014 Q3	$5.14M	Sell	89,078 -4,933	-5%	-$274K	0.44%	53
2014 Q2	$5.31M	Sell	94,011 -4,074	-4%	-$214K	0.45%	50
2014 Q1	$5.04M	Buy	98,085 +25,029	+34%	+$1.26M	0.41%	53
2013 Q4	$3.86M	Buy	73,056 +10,976	+18%	+$539K	0.35%	66
2013 Q3	$2.78M	Sell	62,080 -13,612	-18%	-$603K	0.33%	66
2013 Q2	$3.13M	Buy	+75,692	New	+$3.31M	0.4%	56

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LS Investment Advisors's ABBV Position: Q2 2026 in Review

LS Investment Advisors reduced its AbbVie (ABBV) stake by 5.6% in Q2 2026, selling an estimated $163K and leaving 12,835 shares worth $3.23M. The position accounts for 0.44% of the portfolio, ranked #49.

LS Investment Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.94M in Q4 2020. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

LS Investment Advisors held 12,835 shares of AbbVie worth $3.23M as of Q2 2026.
LS Investment Advisors sold 759 AbbVie shares in Q2 2026, an estimated $163K.
AbbVie made up 0.44% of LS Investment Advisors's portfolio in Q2 2026, its #49 holding.
LS Investment Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
LS Investment Advisors's AbbVie position peaked at $9.94M in Q4 2020.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on LS Investment Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.